Protara Therapeutics (NASDAQ:TARA - Get Free Report) is expected to be issuing its Q1 2025 quarterly earnings data before the market opens on Thursday, May 1st. Analysts expect Protara Therapeutics to post earnings of ($0.47) per share for the quarter.
Protara Therapeutics (NASDAQ:TARA - Get Free Report) last released its quarterly earnings data on Wednesday, March 12th. The company reported ($0.48) earnings per share for the quarter, beating the consensus estimate of ($0.57) by $0.09. On average, analysts expect Protara Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.
Protara Therapeutics Stock Performance
Shares of NASDAQ:TARA traded down $0.74 during mid-day trading on Monday, reaching $3.59. 2,057,254 shares of the company's stock were exchanged, compared to its average volume of 780,709. The business's fifty day moving average price is $4.04 and its 200-day moving average price is $4.01. Protara Therapeutics has a twelve month low of $1.60 and a twelve month high of $10.48. The firm has a market capitalization of $131.81 million, a price-to-earnings ratio of -1.24 and a beta of 1.60.
Insider Buying and Selling
In related news, insider Jacqueline Zummo sold 21,224 shares of the business's stock in a transaction dated Wednesday, March 26th. The stock was sold at an average price of $4.53, for a total transaction of $96,144.72. Following the transaction, the insider now owns 98,861 shares in the company, valued at $447,840.33. The trade was a 17.67 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 12.50% of the stock is owned by insiders.
Analysts Set New Price Targets
A number of research analysts recently weighed in on the company. HC Wainwright reaffirmed a "buy" rating and set a $23.00 price target on shares of Protara Therapeutics in a research note on Monday. Cantor Fitzgerald initiated coverage on shares of Protara Therapeutics in a research report on Friday, March 14th. They issued an "overweight" rating on the stock. Lifesci Capital assumed coverage on shares of Protara Therapeutics in a report on Tuesday, March 11th. They set an "outperform" rating and a $22.00 price target on the stock. Finally, Scotiabank started coverage on Protara Therapeutics in a research note on Wednesday, April 16th. They set a "sector outperform" rating and a $12.00 target price on the stock. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $20.40.
Get Our Latest Stock Analysis on TARA
About Protara Therapeutics
(
Get Free Report)
Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.
Further Reading
Before you consider Protara Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Protara Therapeutics wasn't on the list.
While Protara Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
